Arbutus Biopharma Operating Cycle Over Time
| ABUS Stock | USD 4.13 0.01 0.24% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arbutus Biopharma Performance and Arbutus Biopharma Correlation. Is there potential for Biotechnology market expansion? Will Arbutus introduce new products? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.23) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Arbutus Biopharma Corp's market price often diverges from its book value, the accounting figure shown on Arbutus's balance sheet. Smart investors calculate Arbutus Biopharma's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Arbutus Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Arbutus Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arbutus Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Cycle Analysis
Compare Arbutus Biopharma Corp and related stocks such as ARS Pharmaceuticals, Nanobiotix, and GH Research PLC Operating Cycle Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRY | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 7.8587 | 0.0663 | 9.7 K | 9.7 K | 130 | 117 | 111 |
| NBTX | 361 | 361 | 5.3 K | 122 | 0.2156 | 7.2744 | 338 | 16.5731 | 2.6229 | 6.7 K | 141.7 K | 141.7 K | 217 | 115 | (268) | (242) | (229) |
| GHRS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TNGX | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 95.3501 | 19.7074 | 29.3644 | 29.3644 | 29.3644 | 33.77 | 52.95 |
| BCAX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| SEPN | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 55.1 K | 382 | 439 | 417 |
| EYPT | 338 | 11.4133 | 65.294 | 65.37 | (9.0817) | (162) | 17.0905 | 36.5502 | 494 | 494 | 435 | 343 | 263 | 314 | 232 | 267 | 200 |
| KURA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PROK | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 11.8 K | 10.6 K | 9.4 K |
| SVRA | 52.5812 | 792 | 792 | 792 | 792 | 792 | 792 | 2.5 K | (15.2189) | (15.2189) | 2.4 K | (14.4031) | 26.8785 | 26.8785 | 26.8785 | 24.19 | 22.98 |
Arbutus Biopharma Corp and related stocks such as ARS Pharmaceuticals, Nanobiotix, and GH Research PLC Operating Cycle description
My Equities
My Current Equities and Potential Positions
| Arbutus Biopharma Corp | ABUS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 701 Veterans Circle, |
| Exchange | NASDAQ Exchange |
USD 4.13
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.